Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in Children
Status:
Terminated
Trial end date:
2018-02-14
Target enrollment:
Participant gender:
Summary
In this study we will combine mycophenolate mofetil and imatinib mesylate to treat
steroid-refractory sclerotic/fibrotic type chronic graft-versus-host disease (GVHD) to see
the response rate and to find the safety of combination.